Optimer announced that it had completed enrollment of a Phase III trial of its antibiotic fidaxomicin. Investors, who had hoped to see results from the study by the end of this year, breathed a sigh of relief at the news. "We will complete the analysis of the data from this trial and we expect to report top-line results in the first quarter of 2010," says Michael Chang, Ph.D., President and CEO of Optimer. Optimer's release | Article